Vitamin C alleviates ototoxic effect caused by coadministration of amikacin and furosemide

•Combination of amikacin and furosemide produces ototoxic effects in mice.•The combination impairs hearing threshold in mice by 20% and 50%.•Vitamin C reduces ototoxicity evoked by the combination of amikacin and furosemide. Drug-induced ototoxicity is still a main clinical problem in otolaryngology...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacological reports 2019-04, Vol.71 (2), p.351-356
Main Authors: Zadrozniak, Marek, Szymanski, Marcin, Luszczki, Jarogniew J.
Format: Article
Language:English
Subjects:
Amikacin
Amikacin - administration & dosage
Amikacin - toxicity
Animals
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - toxicity
Ascorbic Acid - administration & dosage
Ascorbic Acid - pharmacology
Diuretics - administration & dosage
Diuretics - toxicity
Drug Safety and Pharmacovigilance
Furosemide
Furosemide - administration & dosage
Furosemide - toxicity
Hearing Loss - chemically induced
Hearing Loss - prevention & control
Isobolography
Linear Models
Male
Mice
Original Article
Ototoxicity
Pharmacotherapy
Pharmacy
Vitamin C
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Combination of amikacin and furosemide produces ototoxic effects in mice.•The combination impairs hearing threshold in mice by 20% and 50%.•Vitamin C reduces ototoxicity evoked by the combination of amikacin and furosemide. Drug-induced ototoxicity is still a main clinical problem in otolaryngology. It is widely known that aminoglycoside antibiotics combined with loop diuretics significantly contribute to permanent ototoxicity. The aim of this study was to find out whether ascorbic acid (vitamin C) is able to reverse or alleviate ototoxicity evoked by systemic (ip) administration of combination of amikacin and furosemide in experimental male albino Swiss mice. Ototoxic combination of amikacin and furosemide was isobolographically evaluated based on the hearing threshold decreasing doses by 20% and 50% (TDD20 and TDD50), respectively. Linear regression analysis was used to determine the TDD20 and TDD50 values for amikacin, furosemide, vitamin C administered alone and in combination (at the fixed-ratio of 1:1). Vitamin C (in a dose of 500 mg/kg, ip) alleviated the impairment in hearing threshold evoked by combined ip administration of amikacin and furosemide (at the fixed-ratio of 1:1) in mice by reducing TDD50 values from 49.82 to 21.56 (p 
ISSN:1734-1140
2299-5684
DOI:10.1016/j.pharep.2019.01.002